论著

24例KCNQ2基因变异癫痫患儿的临床表型与基因型分析

  • 王丽辉 ,
  • 崔丽平 ,
  • 杨花芳 ,
  • 刘兰 ,
  • 唐晓娜 ,
  • 赵青 ,
  • 王欣 ,
  • 李宝广
展开
  • 1.河北省儿童医院神经内科 河北省小儿癫痫与神经疾病重点实验室(河北石家庄 050031)
    2.石家庄市第四医院 儿童保健科(河北石家庄 050011)
杨花芳 电子信箱:yanghuafang2015@126.com

收稿日期: 2023-11-28

  录用日期: 2024-12-13

  网络出版日期: 2025-02-12

基金资助

河北省医学科学研究课题计划项目(20240744)

Clinical phenotype and genotype analysis of 24 epileptic children with KCNQ2 gene variation

  • WANG Lihui ,
  • CUI Liping ,
  • YANG Huafang ,
  • LIU Lan ,
  • TANG Xiaona ,
  • ZHAO Qing ,
  • WANG Xin ,
  • LI Baoguang
Expand
  • 1. Department of Neurology, Hebei Provincial Children's Hospital, Hebei Provincial Key Laboratory of Pediatric Epilepsy and Neurological Diseases, Shijiazhuang 050031, Hebei, China
    2. Department of Child Health, Shijiazhuang Fourth Hospital, Shijiazhuang 050011, Hebei, China

Received date: 2023-11-28

  Accepted date: 2024-12-13

  Online published: 2025-02-12

摘要

目的 探讨KCNQ2基因(OMIM#602235)变异癫痫患儿的临床表型及基因特点。方法 回顾性分析2018年10月至2022年11月经外显子测序发现的KCNQ2基因阳性癫痫患儿的临床资料,总结基因型特点及治疗情况。结果 24例KCNQ2基因变异(NM_172107)癫痫患儿中,男14例、女10例。癫痫首次发作年龄为生后17小时~5岁,其中≤6个月的16例(66.7%)。根据临床预后分为良性家族性新生儿癫痫(BFNE)1例,良性家族性婴儿癫痫(BFIE)6例,不能分类的自限性癫痫综合征4例;KCNQ2-发育性癫痫性脑病(KCNQ2-DEE)13例。基因变异以错义突变为主(62.5%),同时发现7个新的KCNQ2突变位点,其中c.1411C>T评估为致病性变异,c.602G>C、c.1031G>A、c.2159_2173del(p.720_725delinsR)评估为可疑致病变异。24例患儿的中位随访时间为40个月,13例KCNQ2-DEE存在不同程度的发育迟缓,其余11例总体预后较好,认知发育正常。结论 KCNQ2变异患儿癫痫发病年龄主要为新生儿期及婴儿早期。KCNQ2-DEE预后差。建议婴幼儿期不明原因的癫痫发作应尽早行基因检测,以明确诊断。

本文引用格式

王丽辉 , 崔丽平 , 杨花芳 , 刘兰 , 唐晓娜 , 赵青 , 王欣 , 李宝广 . 24例KCNQ2基因变异癫痫患儿的临床表型与基因型分析[J]. 临床儿科杂志, 2025 , 43(2) : 93 -98 . DOI: 10.12372/jcp.2025.23e1140

Abstract

Objective To investigate the clinical and genetic characteristics of children with epilepsy caused by variations of the KCNQ2 gene (OMIM #602235). Methods The clinical data of 24 children with KCNQ2 gene variants (NM_172107) detected by whole-exome sequencing (WES) from October 2018 to November 2022 were analyzed, and the genotypic characteristics and treatment were analyzed. Results A total of 24 children (14 boys and 10 girls) with epilepsy caused by KCNQ2 gene variations were included. The age of the first seizure in these children ranged from 17 hours after birth to 5 years old. Among them, 16 children (66.7%) were younger than 6 months. According to the clinical prognosis, there were 1 case of benign familial neonatal epilepsy (BFNE), 6 cases of benign familial infantile epilepsy (BFIE), 4 cases of self-limited epilepsy syndrome that could not be classified, and 13 cases of KCNQ2-related developmental and epileptic encephalopathy (KCNQ2-DEE). The main genetic variation was missense mutation (62.5%), and 7 new KCNQ2 mutation sites were found. Among them, c.1411C>T was evaluated as pathogenic, c.602G>C, c.1031G>A, c.2159_2173del (p.720_725delinsR) was evaluated as likely pathogenic. The median follow-up time of the 24 patients was 40 months. 13 patients had varying degrees of developmental delay in KCNQ2-DEE, and the remaining 11 patients had good overall prognosis and normal cognitive development. Conclusions The age of seizures associated with KCNQ2 variation is mainly distributed in the neonatal period and early infancy. The prognosis of KCNQ2-DEE is poor. It is recommended that genetic testing should be performed as early as possible for the diagnosis of unexplained seizures in infancy.

参考文献

[1] Ademuwagun IA, Rotimi SO, Syrbe S, et al. Voltage gated sodium channel genes in epilepsy: mutations, functional studies, and treatment dimensions[J]. Front Neurol, 2021, 12: 600050.
[2] Borowicz-Reutt K, Czernia J, Krawczyk M. Genetic background of epilepsy and antiepileptic treatments[J]. Int J Mol Sci, 2023, 24(22): 16280.
[3] 甘靖, 张金秀. KCNQ 钾通道功能障碍相关遗传性癫痫的研究进展[J]. 重庆医学, 2023, 52(6): 919-923.
  Gan J, Zhang JX. Advances in genetic epilepsy associated with KCNQ potassium channel dysfunction[J]. Chongqing Yixue, 2023, 52(6): 919-923.
[4] Yu X, Che F, Zhang X, et al. Clinical and genetic analysis of 23 Chinese children with epilepsy associated with KCNQ2 gene mutations[J]. Epilepsia Open, 2024, 9(5): 1658-1669.
[5] Iftimovici A, Charmet A, Desnous B, et al. Familial KCNQ2 mutation: a psychiatric perspective[J]. Psychiatr Genet, 2024, 34(1): 24-27.
[6] Hou B, Santaniello S, Tzingounis AV. KCNQ2 channels regulate the population activity of neonatal GABAergic neurons ex vivo[J]. Front Neurol, 2023, 14: 1207539.
[7] Gamal El-Din TM, Lantin T, Tschumi CW, et al. Autism-associated mutations in KV7 channels induce gating pore current[J]. Proc Natl Acad Sci U S A, 2021, 118(45): e2112666118.
[8] Wirrell EC, Nabbout R, Scheffer IE, et al. Methodology for classification and definition of epilepsy syndromes with list of syndromes: report of the ILAE Task Force on Nosology and Definitions[J]. Epilepsia, 2022, 63(6): 1333-1348.
[9] Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology[J]. Genet Med, 2015, 17(5): 405-424.
[10] 张平平, 姬辛娜, 高志杰, 等. KCNQ2基因突变相关癫痫患者13例临床表型和基因型分析[J]. 中华神经科杂志, 2021, 54(6): 553-559.
  Zhang PP, Ji XN, Gao ZJ, et al. Clinical phenotype and genotype analysis of 13 patients with epilepsy associated with KCNQ2 gene mutation[J]. Zhonghua Shenjingke Zazhi, 2021, 54 (6): 553-559.
[11] 许艳, 胡兰, 周也群, 等. KCNQ2基因突变致婴儿癫痫伴游走性局灶性发作二例[J]. 中华新生儿科杂志, 2020, 35(4): 306-307.
  Xu Y, Hu L, Zhou YQ, et al. Two cases of infantile epilepsy with wandering focal seizures caused by KCNQ2 gene mutation[J]. Zhonghua Xinshengerke Zazhi, 2020, 35 (4): 306-307.
[12] Lee IC, Chang MY, Liang JS, et al. Ictal and interictal electroencephalographic findings can contribute to early diagnosis and prompt treatment in KCNQ2-associated epileptic encephalopathy[J]. J Formos Med Assoc, 2021, 120(1 Pt 3): 744-754.
[13] Ihara Y, Tomonoh Y, Deshimaru M, et al. Retigabine, a Kv7.2/Kv7.3-channel opener, attenuates drug-induced seizures in knock-in mice harboring Kcnq2 mutations[J]. PLoS One, 2016, 11(2): e0150095.
[14] Ye J, Tang S, Miao P, et al. Clinical analysis and functional characterization of KCNQ2-related developmental and epileptic encephalopathy[J]. Front Mol Neurosci, 2023, 16: 1205265.
[15] Springer K, Varghese N, Tzingounis AV. Flexible stoichiometry: implications for KCNQ2- and KCNQ3-associated neurodevelopmental disorders[J]. Dev Neurosci, 2021, 43(3-4): 191-200.
[16] Kim HJ, Yang D, Kim SH, et al. Clinical characteristics of KCNQ2 encephalopathy[J]. Brain Dev, 2021, 43(2): 244-250.
[17] Falsaperla R, Criscione R, Cimino C, et al. KCNQ2-related epilepsy: genotype-phenotype relationship with tailored antiseizure medication (ASM)-a systematic review[J]. Neuropediatrics, 2023, 54(5): 297-307.
[18] Goto A, Ishii A, Shibata M, et al. Characteristics of KCNQ2 variants causing either benign neonatal epilepsy or developmental and epileptic encephalopathy[J]. Epilepsia, 2019, 60(9): 1870-1880.
[19] Vanoye CG, Desai RR, Ji Z, et al. High-throughput evaluation of epilepsy-associated KCNQ2 variants reveals functional and pharmacological heterogeneity[J]. JCI Insight, 2022, 7(5): e156314.
[20] Xiong J, Chen S, Chen B, et al. A novel KCNQ2 missense variant in non-syndromic intellectual disability causes mild gain-of-function of Kv7.2 channel[J]. Clin Chim Acta, 2022, 530: 74-80.
[21] Bezdekova R, Jelinek T, Kralova R, et al. Necessity of flow cytometry assessment of circulating plasma cells and its connection with clinical characteristics of primary and secondary plasma cell leukaemia[J]. Br J Haematol, 2021, 195(1): 95-107.
文章导航

/